Tag: Chemotherapy induced anemia

According to the National Kidney Foundation, anemia is a common complication of chronic kidney disease, affecting more than 30 million American adults. For patients seeking treatment for anemia, a frequent question arises: which is better, PROCRIT or Aranesp? While both drugs work similarly, their distinct dosing schedules and pharmacokinetic properties are key factors in determining the best choice for an individual's specific needs.

According to the National Kidney Foundation, anemia is a common complication of chronic kidney disease (CKD), affecting millions of people. For certain individuals, the prescription medication Procrit is used for anemia to help manage the condition by stimulating the body's natural red blood cell production.

Procrit, a brand name for epoetin alfa, is an erythropoiesis-stimulating agent (ESA) that helps the body produce more red blood cells. While a detectable increase in immature red blood cells (reticulocytes) can occur within 10 days, a clinically significant rise in hemoglobin and red blood cell count, and thus a reduction in anemia symptoms, typically takes 2 to 6 weeks.